{"pmid":32447102,"title":"Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients.","text":["Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients.","Tocilizumab (TCZ) is used for treating moderate-to-severe Covid-19 pneumonia by targeting interleukin-6 receptors (IL-6Rs) and reducing cytokine release. Yet, in spite of this therapy, patients with vs patients without diabetes have an adverse disease course. In fact, glucose homoeostasis has influenced the outcomes of diabetes patients with infectious diseases. Of the 475 Covid-19-positive patients admitted to infectious disease departments (University of Bologna, University Vanvitelli of Napoli, San Sebastiano Caserta Hospital) in Italy since 1 March 2020, 31 (39.7%) hyperglycaemic and 47 (60.3%) normoglycaemic patients (blood glucose levels >/= 140 mg/dL) were retrospectively evaluated at admission and during their hospital stay. Of note, 20 (64%) hyperglycaemic and 11 (23.4%) normoglycaemic patients had diabetes (P < 0.01). At admission, hyperglycaemic vs normoglycaemic patients had fivefold higher IL-6 levels, which persisted even after TCZ administration (P < 0.05). Intriguingly, in a risk-adjusted Cox regression analysis, TCZ in hyperglycaemic patients failed to attenuate risk of severe outcomes as it did in normoglycaemic patients (P < 0.009). Also, in hyperglycaemic patients, higher IL-6 plasma levels reduced the effects of TCZ, while adding IL-6 levels to the Cox regression model led to loss of significance (P < 0.07) of its effects. Moreover, there was evidence that optimal Covid-19 infection management with TCZ is not achieved during hyperglycaemia in both diabetic and non-diabetic patients. These data may be of interest to currently ongoing clinical trials of TCZ effects in Covid-19 patients and of optimal control of glycaemia in this patient subset.","Diabetes Metab","Marfella, Raffaele","Paolisso, Pasquale","Sardu, Celestino","Bergamaschi, Luca","D'Angelo, Emanuela Concetta","Barbieri, Michelangela","Rizzo, Maria Rosaria","Messina, Vincenzo","Maggi, Paolo","Coppola, Nicola","Pizzi, Carmine","Biffi, Mauro","Viale, Pierluigi","Galie, Nazzareno","Paolisso, Giuseppe","32447102"],"abstract":["Tocilizumab (TCZ) is used for treating moderate-to-severe Covid-19 pneumonia by targeting interleukin-6 receptors (IL-6Rs) and reducing cytokine release. Yet, in spite of this therapy, patients with vs patients without diabetes have an adverse disease course. In fact, glucose homoeostasis has influenced the outcomes of diabetes patients with infectious diseases. Of the 475 Covid-19-positive patients admitted to infectious disease departments (University of Bologna, University Vanvitelli of Napoli, San Sebastiano Caserta Hospital) in Italy since 1 March 2020, 31 (39.7%) hyperglycaemic and 47 (60.3%) normoglycaemic patients (blood glucose levels >/= 140 mg/dL) were retrospectively evaluated at admission and during their hospital stay. Of note, 20 (64%) hyperglycaemic and 11 (23.4%) normoglycaemic patients had diabetes (P < 0.01). At admission, hyperglycaemic vs normoglycaemic patients had fivefold higher IL-6 levels, which persisted even after TCZ administration (P < 0.05). Intriguingly, in a risk-adjusted Cox regression analysis, TCZ in hyperglycaemic patients failed to attenuate risk of severe outcomes as it did in normoglycaemic patients (P < 0.009). Also, in hyperglycaemic patients, higher IL-6 plasma levels reduced the effects of TCZ, while adding IL-6 levels to the Cox regression model led to loss of significance (P < 0.07) of its effects. Moreover, there was evidence that optimal Covid-19 infection management with TCZ is not achieved during hyperglycaemia in both diabetic and non-diabetic patients. These data may be of interest to currently ongoing clinical trials of TCZ effects in Covid-19 patients and of optimal control of glycaemia in this patient subset."],"journal":"Diabetes Metab","authors":["Marfella, Raffaele","Paolisso, Pasquale","Sardu, Celestino","Bergamaschi, Luca","D'Angelo, Emanuela Concetta","Barbieri, Michelangela","Rizzo, Maria Rosaria","Messina, Vincenzo","Maggi, Paolo","Coppola, Nicola","Pizzi, Carmine","Biffi, Mauro","Viale, Pierluigi","Galie, Nazzareno","Paolisso, Giuseppe"],"date":"2020-05-25T11:00:00Z","year":2020,"_id":"32447102","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.diabet.2020.05.005","keywords":["covid-19","diabetes mellitus","interleukin-6"],"locations":["Napoli","Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Treatment"],"weight":1,"_version_":1667698385952440321,"score":9.490897,"similar":[{"pmid":32253759,"title":"Tocilizumab treatment in COVID-19: A single center experience.","text":["Tocilizumab treatment in COVID-19: A single center experience.","Tocilizumab (TCZ), a monoclonal antibody against interleukin-6 (IL-6), emerged as an alternative treatment for COVID-19 patients with a risk of cytokine storms recently. In the present study, we aimed to discuss the treatment response of TCZ therapy in COVID-19 infected patients. The demographic, treatment, laboratory parameters of C-reactive protein (CRP) and IL-6 before and after TCZ therapy and clinical outcome in the 15 COVID-19 patients were retrospectively assessed. Totally 15 patients with COVID-19 were included in this study. Two of them were moderately ill, six were seriously ill and seven were critically ill. The TCZ was used in combination with methylprednisolone in eight patients. Five patients received the TCZ administration twice or more. Although TCZ treatment ameliorated the increased CRP in all patients rapidly, for the four critically ill patients who received an only single dose of TCZ, three of them (No. 1, 2, and 3) still dead and the CRP level in the rest one patient (No. 7) failed to return to normal range with a clinical outcome of disease aggravation. Serum IL-6 level tended to further spiked firstly and then decreased after TCZ therapy in 10 patients. A persistent and dramatic increase of IL-6 was observed in these four patients who failed treatment. TCZ appears to be an effective treatment option in COVID-19 patients with a risk of cytokine storms. And for these critically ill patients with elevated IL-6, the repeated dose of the TCZ is recommended.","J Med Virol","Luo, Pan","Liu, Yi","Qiu, Lin","Liu, Xiulan","Liu, Dong","Li, Juan","32253759"],"abstract":["Tocilizumab (TCZ), a monoclonal antibody against interleukin-6 (IL-6), emerged as an alternative treatment for COVID-19 patients with a risk of cytokine storms recently. In the present study, we aimed to discuss the treatment response of TCZ therapy in COVID-19 infected patients. The demographic, treatment, laboratory parameters of C-reactive protein (CRP) and IL-6 before and after TCZ therapy and clinical outcome in the 15 COVID-19 patients were retrospectively assessed. Totally 15 patients with COVID-19 were included in this study. Two of them were moderately ill, six were seriously ill and seven were critically ill. The TCZ was used in combination with methylprednisolone in eight patients. Five patients received the TCZ administration twice or more. Although TCZ treatment ameliorated the increased CRP in all patients rapidly, for the four critically ill patients who received an only single dose of TCZ, three of them (No. 1, 2, and 3) still dead and the CRP level in the rest one patient (No. 7) failed to return to normal range with a clinical outcome of disease aggravation. Serum IL-6 level tended to further spiked firstly and then decreased after TCZ therapy in 10 patients. A persistent and dramatic increase of IL-6 was observed in these four patients who failed treatment. TCZ appears to be an effective treatment option in COVID-19 patients with a risk of cytokine storms. And for these critically ill patients with elevated IL-6, the repeated dose of the TCZ is recommended."],"journal":"J Med Virol","authors":["Luo, Pan","Liu, Yi","Qiu, Lin","Liu, Xiulan","Liu, Dong","Li, Juan"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32253759","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1002/jmv.25801","keywords":["covid-19","sars-cov-2","tocilizumab","cytokine storms","interleukin-6"],"e_drugs":["tocilizumab","Methylprednisolone"],"topics":["Treatment"],"weight":1,"_version_":1666138493175201792,"score":397.93427},{"pmid":32387320,"title":"Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients.","text":["Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients.","INTRODUCTION: No therapy has yet proven effective in COVID-19. Tocilizumab (TCZ) in patients with severe COVID-19 could be an effective treatment. METHOD: We conducted a retrospective case-control study in the Nord Franche-Comte Hospital, France. We compared the outcome of patients treated with TCZ and patients without TCZ considering a combined primary endpoint: death and/or ICU admissions. RESULTS: Patients with TCZ (n=20) had a higher Charlson comorbidity index (5.3 [+/-2.4] vs 3.4 [+/-2.6], p=0.014), presented with more severe forms (higher level of oxygen therapy at 13 L/min vs 6 L/min, p<0.001), and had poorer biological findings (severe lymphopenia: 676/mm(3) vs 914/mm(3), p=0.037 and higher CRP level: 158 mg/l vs 105 mg/l, p=0.017) than patients without TCZ (n=25). However, death and/or ICU admissions were higher in patients without TCZ than in the TCZ group (72% vs 25%, p=0.002). CONCLUSION: Despite the small sample size and retrospective nature of the work, this result strongly suggests that TCZ may reduce the number of ICU admissions and/or mortality in patients with severe SARS-CoV-2 pneumonia.","Med Mal Infect","Klopfenstein, Timothee","Zayet, Souheil","Lohse, Anne","Balblanc, Jean-Charles","Badie, Julio","Royer, Pierre-Yves","Toko, Lynda","Mezher, Chaouki","Kadiane-Oussou, N'dri Juliette","Bossert, Marie","Bozgan, Ana-Maria","Charpentier, Aline","Roux, Marie-Francoise","Contreras, Remy","Mazurier, Isabelle","Dussert, Pascale","Gendrin, Vincent","Conrozier, Thierry","32387320"],"abstract":["INTRODUCTION: No therapy has yet proven effective in COVID-19. Tocilizumab (TCZ) in patients with severe COVID-19 could be an effective treatment. METHOD: We conducted a retrospective case-control study in the Nord Franche-Comte Hospital, France. We compared the outcome of patients treated with TCZ and patients without TCZ considering a combined primary endpoint: death and/or ICU admissions. RESULTS: Patients with TCZ (n=20) had a higher Charlson comorbidity index (5.3 [+/-2.4] vs 3.4 [+/-2.6], p=0.014), presented with more severe forms (higher level of oxygen therapy at 13 L/min vs 6 L/min, p<0.001), and had poorer biological findings (severe lymphopenia: 676/mm(3) vs 914/mm(3), p=0.037 and higher CRP level: 158 mg/l vs 105 mg/l, p=0.017) than patients without TCZ (n=25). However, death and/or ICU admissions were higher in patients without TCZ than in the TCZ group (72% vs 25%, p=0.002). CONCLUSION: Despite the small sample size and retrospective nature of the work, this result strongly suggests that TCZ may reduce the number of ICU admissions and/or mortality in patients with severe SARS-CoV-2 pneumonia."],"journal":"Med Mal Infect","authors":["Klopfenstein, Timothee","Zayet, Souheil","Lohse, Anne","Balblanc, Jean-Charles","Badie, Julio","Royer, Pierre-Yves","Toko, Lynda","Mezher, Chaouki","Kadiane-Oussou, N'dri Juliette","Bossert, Marie","Bozgan, Ana-Maria","Charpentier, Aline","Roux, Marie-Francoise","Contreras, Remy","Mazurier, Isabelle","Dussert, Pascale","Gendrin, Vincent","Conrozier, Thierry"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32387320","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.medmal.2020.05.001","keywords":["covid-19","sars-cov-2","intensive care unit","mortality","tocilizumab"],"locations":["France"],"countries":["France"],"countries_codes":["FRA|France"],"topics":["Treatment"],"weight":1,"_version_":1666428892698640384,"score":364.9585},{"pmid":32397399,"title":"Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE).","text":["Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE).","Objective: This study aimed to assess the role of Tocilizumab therapy (TCZ) in terms of ICU admission and mortality rate of critically ill patients with severe COVID-19 pneumonia. Design: Patients with COVID-19 pneumonia were prospectively enrolled in SMAtteo COvid19 REgistry (SMACORE). A retrospective analysis of patients treated with TCZ matched using propensity score to patients treated with Standard Of Care (SOC) was conducted. Setting: The study was conducted at IRCCS Policlinico San Matteo Hospital, Pavia, Italy, from March 14, 2020 to March 27, 2020. Participants: Patients with a confirmed diagnosis of COVID-19 hospitalized in our institution at the time of TCZ availability. Interventions: TCZ was administered to 21 patients. The first administration was 8 mg/kg (up to a maximum 800 mg per dose) of Tocilizumab intravenously, repeated after 12 h if no side effects were reported after the first dose. Main Outcomes and Measures: ICU admission and 7-day mortality rate. Secondary outcomes included clinical and laboratory data. Results: There were 112 patients evaluated (82 were male and 30 were female, with a median age of 63.55 years). Using propensity scores, the 21 patients who received TCZ were matched to 21 patients who received SOC (a combination of hydroxychloroquine, azithromycin and prophylactic dose of low weight heparin). No adverse event was detected following TCZ administration. This study found that treatment with TCZ did not significantly affect ICU admission (OR 0.11; 95% CI between 0.00 and 3.38; p = 0.22) or 7-day mortality rate (OR 0.78; 95% CI between 0.06 and 9.34; p = 0.84) when compared with SOC. Analysis of laboratory measures showed significant interactions between time and treatment regarding C-Reactive Protein (CRP), alanine aminotransferase (ALT), platelets and international normalized ratio (INR) levels. Variation in lymphocytes count was observed over time, irrespective of treatment. Conclusions: TCZ administration did not reduce ICU admission or mortality rate in a cohort of 21 patients. Additional data are needed to understand the effect(s) of TCZ in treating patients diagnosed with COVID-19.","Microorganisms","Colaneri, Marta","Bogliolo, Laura","Valsecchi, Pietro","Sacchi, Paolo","Zuccaro, Valentina","Brandolino, Fabio","Montecucco, Carlomaurizio","Mojoli, Francesco","Giusti, Emanuele Maria","Bruno, Raffaele","The Covid Irccs San Matteo Pavia Task Force","32397399"],"abstract":["Objective: This study aimed to assess the role of Tocilizumab therapy (TCZ) in terms of ICU admission and mortality rate of critically ill patients with severe COVID-19 pneumonia. Design: Patients with COVID-19 pneumonia were prospectively enrolled in SMAtteo COvid19 REgistry (SMACORE). A retrospective analysis of patients treated with TCZ matched using propensity score to patients treated with Standard Of Care (SOC) was conducted. Setting: The study was conducted at IRCCS Policlinico San Matteo Hospital, Pavia, Italy, from March 14, 2020 to March 27, 2020. Participants: Patients with a confirmed diagnosis of COVID-19 hospitalized in our institution at the time of TCZ availability. Interventions: TCZ was administered to 21 patients. The first administration was 8 mg/kg (up to a maximum 800 mg per dose) of Tocilizumab intravenously, repeated after 12 h if no side effects were reported after the first dose. Main Outcomes and Measures: ICU admission and 7-day mortality rate. Secondary outcomes included clinical and laboratory data. Results: There were 112 patients evaluated (82 were male and 30 were female, with a median age of 63.55 years). Using propensity scores, the 21 patients who received TCZ were matched to 21 patients who received SOC (a combination of hydroxychloroquine, azithromycin and prophylactic dose of low weight heparin). No adverse event was detected following TCZ administration. This study found that treatment with TCZ did not significantly affect ICU admission (OR 0.11; 95% CI between 0.00 and 3.38; p = 0.22) or 7-day mortality rate (OR 0.78; 95% CI between 0.06 and 9.34; p = 0.84) when compared with SOC. Analysis of laboratory measures showed significant interactions between time and treatment regarding C-Reactive Protein (CRP), alanine aminotransferase (ALT), platelets and international normalized ratio (INR) levels. Variation in lymphocytes count was observed over time, irrespective of treatment. Conclusions: TCZ administration did not reduce ICU admission or mortality rate in a cohort of 21 patients. Additional data are needed to understand the effect(s) of TCZ in treating patients diagnosed with COVID-19."],"journal":"Microorganisms","authors":["Colaneri, Marta","Bogliolo, Laura","Valsecchi, Pietro","Sacchi, Paolo","Zuccaro, Valentina","Brandolino, Fabio","Montecucco, Carlomaurizio","Mojoli, Francesco","Giusti, Emanuele Maria","Bruno, Raffaele","The Covid Irccs San Matteo Pavia Task Force"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32397399","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3390/microorganisms8050695","keywords":["covid-19 pneumonia","icu","mortality rate","off label therapy","propensity score matching","tocilizumab"],"locations":["Pavia","Italy","Tocilizumab"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"e_drugs":["Azithromycin","Hydroxychloroquine","tocilizumab","Heparin"],"topics":["Treatment"],"weight":1,"_version_":1666714494985830400,"score":354.73853},{"pmid":32482597,"title":"Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study.","text":["Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study.","BACKGROUND: Tocilizumab (TCZ), a humanized monoclonal antibody targeting the interleukin-6 (IL-6) receptor, has been proposed for the treatment of COVID-19 patients; however, limited data are available on the safety and efficacy. METHODS: We performed a retrospective study on severe COVID-19 patients with hyper-inflammatory features admitted outside intensive care units (ICUs). Patients treated with intravenous TCZ in addition to standard of care were compared to patients treated with standard of care alone. Safety and efficacy were assessed over a 28-day follow-up. RESULTS: 65 patients were included. Among them, 32 were treated with TCZ. At baseline, all patients were on high-flow supplemental oxygen and most (78% of TCZ patients and 61% of standard treatment patients) were on non-invasive ventilation. During the 28-day follow-up, 69% of TCZ patients experienced a clinical improvement compared to 61% of standard treatment patients (p = 0.61). Mortality was 15% in the tocilizumab group and 33% in standard treatment group (p = 0.15). In TCZ group, at multivariate analysis, older age was a predictor of death, whereas higher baseline PaO2:FiO2 was a predictor of clinical improvement at day 28. The rate of infection and pulmonary thrombosis was similar between the two groups. CONCLUSIONS: At day 28, clinical improvement and mortality were not statistically different between tocilizumab and standard treatment patients in our cohort. Bacterial or fungal infections were recorded in 13% of tocilizumab patients and in 12% of standard treatment patients. Confirmation of efficacy and safety will require ongoing controlled trials.","Eur J Intern Med","Campochiaro, Corrado","Della-Torre, Emanuel","Cavalli, Giulio","De Luca, Giacomo","Ripa, Marco","Boffini, Nicola","Tomelleri, Alessandro","Baldissera, Elena","Rovere-Querini, Patrizia","Ruggeri, Annalisa","Monti, Giacomo","De Cobelli, Francesco","Zangrillo, Alberto","Tresoldi, Moreno","Castagna, Antonella","Dagna, Lorenzo","32482597"],"abstract":["BACKGROUND: Tocilizumab (TCZ), a humanized monoclonal antibody targeting the interleukin-6 (IL-6) receptor, has been proposed for the treatment of COVID-19 patients; however, limited data are available on the safety and efficacy. METHODS: We performed a retrospective study on severe COVID-19 patients with hyper-inflammatory features admitted outside intensive care units (ICUs). Patients treated with intravenous TCZ in addition to standard of care were compared to patients treated with standard of care alone. Safety and efficacy were assessed over a 28-day follow-up. RESULTS: 65 patients were included. Among them, 32 were treated with TCZ. At baseline, all patients were on high-flow supplemental oxygen and most (78% of TCZ patients and 61% of standard treatment patients) were on non-invasive ventilation. During the 28-day follow-up, 69% of TCZ patients experienced a clinical improvement compared to 61% of standard treatment patients (p = 0.61). Mortality was 15% in the tocilizumab group and 33% in standard treatment group (p = 0.15). In TCZ group, at multivariate analysis, older age was a predictor of death, whereas higher baseline PaO2:FiO2 was a predictor of clinical improvement at day 28. The rate of infection and pulmonary thrombosis was similar between the two groups. CONCLUSIONS: At day 28, clinical improvement and mortality were not statistically different between tocilizumab and standard treatment patients in our cohort. Bacterial or fungal infections were recorded in 13% of tocilizumab patients and in 12% of standard treatment patients. Confirmation of efficacy and safety will require ongoing controlled trials."],"journal":"Eur J Intern Med","authors":["Campochiaro, Corrado","Della-Torre, Emanuel","Cavalli, Giulio","De Luca, Giacomo","Ripa, Marco","Boffini, Nicola","Tomelleri, Alessandro","Baldissera, Elena","Rovere-Querini, Patrizia","Ruggeri, Annalisa","Monti, Giacomo","De Cobelli, Francesco","Zangrillo, Alberto","Tresoldi, Moreno","Castagna, Antonella","Dagna, Lorenzo"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32482597","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.ejim.2020.05.021","keywords":["covid-19","coronavirus","efficacy","interleukin-6","italy","safety","tocilizumab"],"e_drugs":["tocilizumab"],"topics":["Treatment"],"weight":1,"_version_":1668532114910347264,"score":344.38843},{"pmid":32359035,"title":"Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19.","text":["Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19.","OBJECTIVES: No agent has yet been proven to be effective for the treatment of patients with severe COVID-19. METHODS: We conducted a pilot prospective open, single-arm multicentre study on off-label use of tocilizumab (TCZ) involving 63 hospitalised adult patients (56 males, age 62.6+/-12.5) with severe COVID-19. Clinical and laboratory parameters were prospectively collected at baseline, day 1, 2, 7 and 14. No moderate-to severe adverse events attributable to TCZ were recorded. RESULTS: We observed a significant improvement in the levels of ferritin, C-reactive protein, D-dimer. The ratio of the partial pressure of oxygen (Pa02) to the fraction of inspired oxygen (Fi02) improved (mean+/-SD Pa02/Fi02 at admission: 152+/-53; at day 7: 283.73 +/- 115.9, at day 14: 302.2 +/- 126, p<0.05). The overall mortality was 11%; D-dimer level at baseline, but not IL-6 levels were predictors of mortality. TCZ administration within 6 days from admission in the hospital was associated with an increased likelihood of survival (HR 2.2 95%CI 1.3-6.7, p<0.05). CONCLUSIONS: In hospitalised adult patients with severe COVID-19, TCZ could be a safe option. An improvement in respiratory and laboratory parameters was observed. Future controlled trials in patients with severe illness are urgently needed to confirm the definite benefit with IL-6 target therapy.","Clin Exp Rheumatol","Sciascia, Savino","Apra, Franco","Baffa, Alessandra","Baldovino, Simone","Boaro, Daniela","Boero, Roberto","Bonora, Stefano","Calcagno, Andrea","Cecchi, Irene","Cinnirella, Giacoma","Converso, Marcella","Cozzi, Martina","Crosasso, Paola","De Iaco, Fabio","Di Perri, Giovanni","Eandi, Mario","Fenoglio, Roberta","Giusti, Massimo","Imperiale, Daniele","Imperiale, Gianlorenzo","Livigni, Sergio","Manno, Emilpaolo","Massara, Carlo","Milone, Valeria","Natale, Giuseppe","Navarra, Mauro","Oddone, Valentina","Osella, Sara","Piccioni, Pavilio","Radin, Massimo","Roccatello, Dario","Rossi, Daniela","32359035"],"abstract":["OBJECTIVES: No agent has yet been proven to be effective for the treatment of patients with severe COVID-19. METHODS: We conducted a pilot prospective open, single-arm multicentre study on off-label use of tocilizumab (TCZ) involving 63 hospitalised adult patients (56 males, age 62.6+/-12.5) with severe COVID-19. Clinical and laboratory parameters were prospectively collected at baseline, day 1, 2, 7 and 14. No moderate-to severe adverse events attributable to TCZ were recorded. RESULTS: We observed a significant improvement in the levels of ferritin, C-reactive protein, D-dimer. The ratio of the partial pressure of oxygen (Pa02) to the fraction of inspired oxygen (Fi02) improved (mean+/-SD Pa02/Fi02 at admission: 152+/-53; at day 7: 283.73 +/- 115.9, at day 14: 302.2 +/- 126, p<0.05). The overall mortality was 11%; D-dimer level at baseline, but not IL-6 levels were predictors of mortality. TCZ administration within 6 days from admission in the hospital was associated with an increased likelihood of survival (HR 2.2 95%CI 1.3-6.7, p<0.05). CONCLUSIONS: In hospitalised adult patients with severe COVID-19, TCZ could be a safe option. An improvement in respiratory and laboratory parameters was observed. Future controlled trials in patients with severe illness are urgently needed to confirm the definite benefit with IL-6 target therapy."],"journal":"Clin Exp Rheumatol","authors":["Sciascia, Savino","Apra, Franco","Baffa, Alessandra","Baldovino, Simone","Boaro, Daniela","Boero, Roberto","Bonora, Stefano","Calcagno, Andrea","Cecchi, Irene","Cinnirella, Giacoma","Converso, Marcella","Cozzi, Martina","Crosasso, Paola","De Iaco, Fabio","Di Perri, Giovanni","Eandi, Mario","Fenoglio, Roberta","Giusti, Massimo","Imperiale, Daniele","Imperiale, Gianlorenzo","Livigni, Sergio","Manno, Emilpaolo","Massara, Carlo","Milone, Valeria","Natale, Giuseppe","Navarra, Mauro","Oddone, Valentina","Osella, Sara","Piccioni, Pavilio","Radin, Massimo","Roccatello, Dario","Rossi, Daniela"],"date":"2020-05-03T11:00:00Z","year":2020,"_id":"32359035","source":"PubMed","week":"202018|Apr 27 - May 03","e_drugs":["tocilizumab"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138495359385600,"score":321.40903}]}